This website is for UK Healthcare Professionals only

Contact us

Please complete the form below and a member of the BOTOX® (botulinum toxin type A) team will get back to you.

Please fill in your details below only if you are a UK registered healthcare professional and would like to be contacted by an AbbVie representative.

 

BOTOX® (botulinum toxin type A) is indicated for the treatment of focal spasticity including: wrist and hand disability due to upper limb spasticity associated with stroke in adults; ankle and foot disability due to lower limb spasticity associated with stroke in adults.1

The BOTOX® (botulinum toxin type A) prescribing information and adverse event reporting information can be found at the bottom of the page. 

Please enter First name
Please enter Last name
E-mail address is not valid
Please enter Hospital name
Please enter Hospital postcode

Please select the items you are interested in:

Request a meeting with your local AbbVie representative
Please select one field.

Please note that there may be certain circumstances where we contact you in relation to important AbbVie product information which we are required to provide to you or your patients as a matter of law, or in order to comply with the obligations we owe to you or them. This type of communication does not constitute promotional communication.

You can withdraw your consent at any time by using the unsubscribe option in the email or contacting [email protected]. For further information about AbbVie’s privacy practices, please refer to the AbbVie Privacy notice.

Request a meeting with your local AbbVie representative
Please select one field.


Please refer to the AbbVie privacy notice here for more information on how AbbVie processes your personal data and your data privacy rights.

*Denotes mandatory field

Incorrect. Please try again.

 

References

1. BOTOX® Summary of Product Characteristics. Available at: www.medicines.org.uk. Accessed January 2023

 

Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use.

Date of preparation: January 2023. UK-BTX-220212.